Paris, January 30, 2025 - Sanofi reported a 10.3% sales increase in its fourth-quarter 2024 report. Sales of Beyfortus, a treatment for respiratory syncytial virus, surprisingly performed better in the fourth quarter performance, surpassed forecasts by doubling the sales to €841 million. Sales of asthma drug Dupixent also grew by 16% to €3.46 billion but fell short meeting the expectation.

In the quarter Sanofi reported a decrease of 7.7% to €2.08 billion due to spending increase in research and development. On the bottom line, the business EPS was reported to decrease 14.9% year over year to €1.31, the drop is due to currency fluctuations that affect 11% negatively at Constant Exchange Rates.

The EPS based on International Financial Reporting Standards is €0.54 and that is a comprehensive view of the company's profitability.

Sanofi ADR (SNY, Financial) has decided to focus solely on pharmaceuticals and vaccines by divesting its controlling stake in its consumer health unit, Opella, to Clayton Dubilier & Rice (CD&R) for an enterprise value of nearly €17 billion and the sale of Opella is expected to close in the second quarter of 2025.

The proceeds from the sale of Sanofi's stake in Opella will be used to provide shareholder returns. This means the funds will likely include the €5 billion buyback program for 2025 which was announced following the divestiture decision.

The company's guidance for 2025 is between 5% to 9% sales growth with modest spending for research and development than in 2024. The company demonstrated betterment in balance sheet while having an improvement in its business.

Make more informed investment decisions by visiting GuruFocus today and deep dive into Sanofi's performance with charts, breakdowns, 30-year financial data, investment gurus and politicians' portfolio, and more!